1. How Can we Improve Outcomes for the Elderly Patient with AML?

3. The Challenge of Managing Older Patients With AML: EUROCARE-5 (2000-2007)

4. Front-Line Treatment Outcomes in Older Patients With AML

5. Poorer Outcomes With Undertreatment of Older Patients

6. Clinical and Biological Factors Affecting Treatment Outcomes

7. Case #1: Fit Elderly Patient With Favorable-Risk Cytogenetics

8. Treating Fit Patients With Favorable-Risk Cytogenetics

9. Case #2: Fit Elderly Patient With Poor-Risk Cytogenetics

10. Treating Fit Patients With Poor-Risk Cytogenetics

11. Treating Fit Patients With Poor-Risk Cytogenetics (cont.)

12. Considerations in Selecting a Treatment Option

13. Effect of Antecedent Hematologic Disease Other Than MDS on Outcomes Danish National Acute Leukemia Registry

14. Decitabine in AML: Multicenter DACO-016 Phase 3 Trial

15. DACO-016: OS Analysis By Time Point

16. Azacitidine in AML 20-30 and AML 30+: Austrian Azacitidine Registry

17. Azacitidine in Older Patients With AML 30+: Multicenter AZA-AML-001 Phase 3 Trial

18. AZA-AML-001: Analysis by CCR Treatment

19. AZA-AML-001: Analysis of Patients With AML-MRC by CCR Treatment

20. Hematologic Response With Hypomethylating Agents: DACO-016 and AZA-AML-001

21. Case #3: Unfit Elderly Patient With Comorbidities

22. Treating Unfit Elderly Patients

23. Selecting a Hypomethylating Agent in AML: Evidence From MDS

24. Selecting a Hypomethylating Agent in AML: DACO-016, AZA-AML-001, and Austrian Azacitidine Registry

25. Assessing Response to Hypomethylating Agents

26. Managing Toxicities Associated With Hypomethylating Agents

27. Conclusions

28. Abbreviations

29. Abbreviations (cont)

30. Abbreviations (cont)